Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet.
Institute of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Blegdamsvej, Denmark.
Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):364-371. doi: 10.1097/MED.0000000000000570.
To summarize the recent developments in considering Hashimoto's thyroiditis as a risk factor for thyroid cancer.
Modern approaches to understanding the co-occurrence of Hashimoto's thyroiditis and thyroid cancer have consistently found increased prevalence of both conditions, separately as well as of their coexistence. The inflammatory process in Hashimoto's thyroiditis is understood as a potential risk factor for thyroid cancer development. This has also provided a better understanding of the limitations in the current diagnostic and follow-up armamentarium for both conditions, resulting in international guidelines from the clinical and scientific societies. Other recent developments call for a paradigm shift in guidelines on thyroid carcinomas when lymphocytic infiltration is present, which potentially should always be considered the case at least in areas of sufficient iodine intake.
The literature of Hashimoto's thyroiditis as a risk factor for thyroid cancer is reviewed over the last year to highlight new developments in the understanding of their association and future clinical implications.
总结近年来将桥本甲状腺炎作为甲状腺癌风险因素的研究进展。
理解桥本甲状腺炎与甲状腺癌共同发生的现代方法发现,这两种疾病的患病率均有所增加,分别为单独存在和共存时的患病率。桥本甲状腺炎的炎症过程被认为是甲状腺癌发展的潜在危险因素。这也使人们更好地理解了当前这两种疾病的诊断和随访手段的局限性,从而产生了来自临床和科学学会的国际指南。其他最新进展呼吁在有淋巴细胞浸润的情况下,对甲状腺癌的指南进行范式转变,在碘摄入充足的地区,这种情况至少应该被认为是普遍存在的。
综述了过去一年来桥本甲状腺炎作为甲状腺癌风险因素的文献,以强调对其相关性的新认识及其未来的临床意义。